TLR4 and Parkinson disease: Collectively, we elucidate that FMT treatment attenuates the gut microbiota dysbiosis and protects the PD model, in which suppression of the inflammation mediated by the LPS-TLR4 signaling pathway both in the gut and the brain possibly plays a significant role.